Every 10-Q that Alignment Healthcare, Inc. (ALHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALHC filings page.
Alignment Healthcare, Inc. reported strong growth for the three months ended March 31, 2026, moving to profitability while expanding membership. Total revenues rose 33.3% year over year to $1.24 billion, driven mainly by earned premiums of $1.23 billion.
Health plan membership grew 30.9% to 284,800 members. The medical benefits ratio was 88.2%, essentially flat versus 88.4% a year earlier, indicating the company absorbed rapid growth without materially higher medical cost ratios.
Income from operations improved to $15.5 million from a loss of $5.4 million, and net income reached $11.4 million compared with a net loss of $9.4 million. Diluted net income per share was $0.05, versus a diluted loss per share of $0.05 in the prior-year period.
Adjusted metrics also strengthened: Adjusted EBITDA increased 87.6% to $37.9 million and adjusted gross profit rose 36.1% to $145.9 million. The company ended the period with $705.6 million of cash and cash equivalents, long-term debt of $323.6 million (carrying value), and total stockholders’ equity of $206.9 million.
Alignment Healthcare (ALHC) reported Q3 2025 results showing strong top-line growth and a return to profitability. Revenue rose to $993.7 million from $692.4 million a year ago, driven by earned premiums of $983.7 million. Medical expenses were $868.0 million and SG&A was $110.0 million, yielding operating income of $7.7 million.
Net income was $3.7 million versus a $26.4 million loss last year, with diluted EPS of $0.02. Year-to-date, revenue reached $2.94 billion and net income was $10.0 million. Cash and cash equivalents were $618.1 million as of September 30, 2025, supported by $190.3 million of net cash provided by operating activities year-to-date. Long-term debt stood at $322.7 million (carrying value) tied to 4.25% convertible senior notes due 2029. Medical expenses payable increased to $528.8 million from $289.8 million at December 31, 2024. Shares outstanding were 199,988,515 as of September 30, 2025; as of October 27, 2025, they were 200,091,742.